Der Onkologe

, Volume 18, Issue 12, pp 1147–1148

HPV-Impfung zur posttherapeutischen Prophylaxe bei Frauen nach Cervix-, Vulva- oder Vaginalläsionen

Journal Club
  • 130 Downloads

HPV vaccination for post-therapeutic prophylaxis in women with cervical, vulval or vaginal dysplasia

Literatur

  1. 1.
    FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915–1927CrossRefGoogle Scholar
  2. 2.
    Garland SM et al (2007) Future I Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943PubMedCrossRefGoogle Scholar
  3. 3.
    Garland SM on behalf of the HPV PATRICIA Study Group (2011) Does the HPV-16/18 AS04-adjuvanted vaccine benefit women with cervical disease? EUROGIN, Lissabon, SS 9-3. (http://www.eurogin.com/2011/programoverview.html) (see Abstracts PDF, page 60)Google Scholar
  4. 4.
    Haupt RM et al (2011) Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 1 29:2632–2642CrossRefGoogle Scholar
  5. 5.
    Joura EA et al (2012) Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344:1–14Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Gynäkologische TumorimmunologieKlinik für Gynäkologie CCM/CBF, Charité - Universitätsmedizin BerlinBerlin Deutschland

Personalised recommendations